Table 1.
Baseline characteristics of study participants.
| Variables | TBQT (n = 160) | TAD (n = 159) | BQT (n = 149) | p | TBQT vs. BQT; p | TAD vs. BQT; p |
|---|---|---|---|---|---|---|
| Age (y) | 44.7 ± 13.7 | 44.1 ± 13.7 | 42.0 ± 14.1 | 0.198 | 0.085 | 0.191 |
| Sex | 0.157 | 0.087 | 0.059 | |||
| Male | 59 (36.9) | 71 (44.7) | 84 (56.4) | |||
| Female | 101 (63.1) | 88 (55.3) | 65 (43.6) | |||
| BMI (kg/m2) | 23.7 ± 3.5 | 24.0 ± 4.0 | 24.0 ± 3.4 | 0.817 | 0.575 | 0.978 |
| Alcohol drinking | 38 (23.8) | 45 (28.3) | 39 (26.2) | 0.651 | 0.622 | 0.675 |
| Smoking | 27 (16.9) | 26 (16.4) | 36 (24.2) | 0.152 | 0.112 | 0.088 |
| Marital status | 0.110 | 0.593 | 0.054 | |||
| Married | 142 (88.6) | 133 (83.0) | 139 (90.6) | |||
| Unmarried | 18 (11.4) | 27 (17.0) | 14 (9.4) | |||
| Disease duration (m) | 0.525 | 0.793 | 0.425 | |||
| ≤1 | 137 (85.6) | 129 (81.1) | 126 (84.6) | |||
| >1 | 23 (14.4) | 30 (18.9) | 24 (15.4) | |||
| Clinical condition | ||||||
| Diabetes | 6 (3.7) | 9 (5.7) | 9 (6.0) | 0.615 | 0.349 | 0.887 |
| Hypertension | 16 (10.0) | 20 (12.6) | 11 (7.4) | 0.317 | 0.416 | 0.130 |
| Severe renal insufficiency | 1 (0.6) | 4 (2.5) | 1 (0.7) | - | - | - |
| Others | 19 (11.9) | 22 (13.8) | 10 (6.7) | 0.119 | 0.120 | 0.061 |
| DOB, median (IQR) | 11.9 (5.7, 24.3) | 13.1 (6.6, 25.9) | 13.2 (7.4, 28.7) | 0.236 | 0.091 | 0.449 |
Categorical variables are expressed as the number of patients, accompanied by percentages in parentheses, while continuous variables are presented as the mean ± standard deviation (SD). Disease duration is defined as the duration of patients self-reported symptoms (epigastric pain, gastric acid reflux, belching, abdominal bloating and heartburn) when outpatient visit. BMI, body mass index; IQR, interquartile range; DOB, differences over baseline; BQT, rabeprazole 10 mg twice daily, compound bismuth aluminate granules 2.6 g thrice daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily; TAD, tegoprazan 50 mg twice daily, amoxicillin 1 g thrice daily; TBQT, tegoprazan 50 mg twice daily, compound bismuth aluminate granules 2.6 g thrice daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily.